Silexion Therapeutics Corp
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
SLXN$0.12-14.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| 2024 | 2023 | |
|---|---|---|
| OPERATING EXPENSES: | ||
| Research and development (including $1,796 and $69 from related party, for the year ended December 31, 2024 and December 31, 2023, respectively) | $5,815 | $3,708 |
| General and administrative (including $2,972 and $48 from related party, for the year ended December 31, 2024 and December 31, 2023, respectively) | 6,756 | 973 |
| TOTAL OPERATING EXPENSES | 12,571 | 4,681 |
| OPERATING LOSS | 12,571 | 4,681 |
| Financial expenses (income), net (including $(1,249) and $83 from related party, for the year ended December 31, 2024 and December 31, 2023, respectively) | 3,938 | 395 |
| LOSS BEFORE INCOME TAX | $16,509 | $5,076 |
| INCOME TAX | 10 | 32 |
| NET LOSS FOR THE YEAR | $16,519 | $5,108 |
| Attributable to: | ||
| Equity holders of the Company | 16,443 | 4,942 |
| Non-controlling interests | 76 | 166 |
| $16,519 | $5,108 | |
| LOSS PER ORDINARY SHARE, BASIC AND DILUTED* | $26.36 | $44.23 |
|---|---|---|
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE*: | 623,846 | 111,726 |
- All share amounts have been retroactively adjusted to reflect a 1-for-9 reverse share split as discussed in Note 1h
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.